Glycerophosphodiester phosphodiesterase domain-containing protein 3 (GDPD3)

Glycerophosphodiester phosphodiesterase domain-containing protein 3 (GDPD3) is a membrane-associated enzyme functioning predominantly as a lysophospholipase D. It hydrolyzes lysoglycerophospholipids to produce lipid signaling mediators such as lysophosphatidic acid (LPA) and cyclic phosphatidic acid (cPA)[3][4]. GDPD3 localizes to the endoplasmic reticulum and regulates critical cellular processes including lipid metabolism, immune cell differentiation, cell proliferation, and survival. It is essential for the maintenance of cancer stem cell properties in chronic myelogenous leukemia, acting via regulation of lipid signaling pathways and suppression of the AKT/mTORC1 signaling axis[2][4]. GDPD3 may serve as a therapeutic target and biomarker in oncology and immune modulation, but further research is needed to define its druggability and therapeutic index[1][2][3].

Other names

GDE7Lysophospholipase D GDPD3Glycerophosphodiester phosphodiesterase 7MGC4171

Inhibition or modulation of GDPD3 is postulated to reduce lysophospholipid-mediated signaling (notably, LPA/cPA production), which may restrict maintenance and self-renewal capacity of CML stem cells and impact cancer relapse[2][4]. Modulation may also alter immune responses and trophoblast cell function via PI3K/AKT pathway control[1].